Abstract

ObjectiveBone-marrow derived endothelial progenitor cells (EPCs) play an important role in tumor neovasculature. Due to their tumor homing property, EPCs are regarded as promising targeted vectors for delivering therapeutic agents in cancer treatment. Consequently, non-invasive confirmation of targeted delivery via imaging is urgently needed. This study shows the development and application of a novel dual-modality probe for in vivo non-invasively tracking of the migration, homing and differentiation of EPCs.MethodsThe paramagnetic/near-infrared fluorescence probe Conjugate 1 labeled EPCs were systemically transplanted into mice bearing human breast MDA-MB-231 tumor xenografts. Magnetic resonance imaging (MRI) and near-infrared (NIR) fluorescence optical imaging were performed at different stages of tumor development. The homing of EPCs and the tumor neovascularization were further evaluated by immunofluorescence.ResultsConjugate 1 labeled EPCs can be monitored in vivo by MRI and NIR fluorescence optical imaging without altering tumor growth for up to three weeks after the systemic transplantation. Histopathological examination confirmed that EPCs were recruited into the tumor bed and then incorporated into new vessels two weeks after the transplantation. Tumor size and microvessel density was not influenced by EPCs transplantation in the first three weeks.ConclusionsThis preclinical study shows the feasibility of using a MRI and NIR fluorescence optical imaging detectable probe to non-invasively monitor transplanted EPCs and also provides strong evidence that EPCs are involved in the development of endothelial cells during the tumor neovascularization.

Highlights

  • The fact that tumor growth and metastasis depend on neovascularization promotes extensive investigations on its role in tumor progression [1]

  • Conjugate 1 labeled endothelial progenitor cells (EPCs) can be monitored in vivo by Magnetic resonance imaging (MRI) and NIR fluorescence optical imaging without altering tumor growth for up to three weeks after the systemic transplantation

  • Histopathological examination confirmed that EPCs were recruited into the tumor bed and incorporated into new vessels two weeks after the transplantation

Read more

Summary

Introduction

The fact that tumor growth and metastasis depend on neovascularization promotes extensive investigations on its role in tumor progression [1]. Earlier studies have demonstrated the contribution of the bone marrow derived endothelial progenitor cells (EPCs) in tumor neovascularization [3,4,5]. The differences in phenotype characterization of EPCs and the confusion of EPCs with other perivascular cells have been suggested as possible reasons of different observations by previous reports [4,6]. Such inconsistent results, along with highly complex mechanism involved in the tumor vascularization, promote extended investigations to further understand the function of EPCs in the neovascularization and tumor development

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call